Dataset opportunity
Eclevar — Medical Imaging Dataset Opportunity
Large medical imaging dataset held by Eclevar, usable for Diagnostic AI and Computer Vision.
Score
42.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
63%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI-Powered Diagnostic Imaging market = $3.46 billion in 2024, CAGR 26.40% (source: AI-Powered Diagnostic Imaging Market Report 2032). [1]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Large
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
As a Clinical Research Organization specializing in medical devices under EU MDR, Eclevar possesses a significant Medical Imaging Dataset. This collection, sourced directly from clinical trials, is linked to regulatory files and medical records, providing a high-fidelity foundation for developing, training, and validating robust Diagnostic AI algorithms.
The business value is underscored by the Global AI-Powered Diagnostic Imaging market, which was valued at $3.46 billion in 2024 and is projected to grow at a 26.40% CAGR. [1] While access is complex due to GDPR/HIPAA regulations and clinical trial agreements, the curated, regulatory-grade quality of this data makes it a rare and essential asset for AI firms seeking a competitive edge and regulatory approval. ⚠ Diligence (valuable data, access to negotiate): Clinical data is subject to strict GDPR and HIPAA regulations.; Primary data ownership typically resides with medical device manufacturers (clients).; Access requires navigating complex clinical trial agreements and ethical committee approvals. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves the holder, Eclevar, owns a recurring pipeline of high-quality, regulatory-grade medical data from over 50 device programs conducted since 2020. The dataset, which includes medical imaging, is generated through post-market clinical investigations under stringent EU MDR compliance, with a track record of zero major non-conformities. For diagnostic AI companies, this represents a rare opportunity to acquire de-risked, compliant data to train and validate algorithms in a booming market projected to grow at over 26% annually.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Deep Qualification90
⚠ needs review — Eclevar is a service provider (CRO) that manages clinical trial data for its clients; it does not own this data, which belongs to the medical device manufacturers (sponsors) and is subject to strict GDPR regulations. [data is owned by the company's customers]
- Dataset Volume80
5 evidence hits, explicit data-volume mention
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand for high-quality medical imaging data is exceptionally high, driven by a market for AI in diagnostics that is growing at a 26.40% CAGR. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility26
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility50
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength86
5 evidence types, 5 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
surplus=medium — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit42
⚠ review — Eclevar is a Contract Research Organization (CRO) whose core business is selling clinical trial and data management services to medical device companies; it does not own the resulting data, making it a service provider and a bad target. Issues: Core business is providing services (clinical trials, data management, regulatory strategy) for which data is the deliverable, not a by-product. [2, 7, 9]; As a CRO, it manages data on behalf of its clients (the sponsors), who retain ultimate r
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
API access
This indicates the use of structured Data Management Plans for clinical trials, ensuring the resulting multimodal data is auditable and formatted for sophisticated AI model development.
Downloads / exports
This shows an established operational presence in key European and Japanese markets, suggesting their data collection and governance practices meet multiple international regulatory standards.
Regulatory records
The holder has successfully delivered over 50 device programs under the stringent EU MDR, proving a consistent and scalable source of regulatory-grade data from post-market clinical investigations.
Medical records / imaging
As a specialized Clinical Research Organization, the company generates imaging data directly from PMCF clinical investigations, providing the real-world evidence highly sought after for training diagnostic AI.
Data-volume signal
This demonstrates exceptional data quality and compliance, with zero major non-conformities across submissions to Notified Bodies, a critical differentiator for buyers needing defensible training data.
Deal room
Deal Room — Eclevar — Medical Imaging Dataset Opportunity
Medical Imaging Dataset (Image, healthcare). Best AI use-case: Diagnostic AI. Target buyers: Medical-AI & diagnostic-imaging companies. Market: Global AI-Powered Diagnostic Imaging market = $3.46 billion in 2024, CAGR 26.40% (source: AI-Powered Diagnostic Imaging Market Report 2032). [1]. Rarity: Medium; accessibility: Restricted. Key risk: Mixed ownership — GDPR-sensitive (PII review). Recommended deal structure: Data Sharing Agreement. Investment score 42.5/100.
Buyer persona
Medical-AI & diagnostic-imaging companies
The type of company or team most likely to buy or use this dataset — the target on the demand side.Market
Global AI-Powered Diagnostic Imaging market = $3.46 billion in 2024, CAGR 26.40% (source: AI-Powered Diagnostic Imaging Market Report 2032). [1]
A rough read on demand and price band for this data, from market signals ($ = niche, $$$ = high AI-buyer demand).Risk
Mixed ownership — GDPR-sensitive (PII review)
The main legal and compliance constraints on using or transferring this data — PII/GDPR, licensing rights, regulatory limits.Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Coverage
Scanned sources
Deliverable
Premium dataset report
Eclevar API-Accessible — a Moderate api-accessible dataset (Multimodal modality) in the healthcare domain. Primary AI use-case: RAG. Market signal: Global Medical Device CRO Market = $7.75 billion in 2023, CAGR 8.95% (2024-2030) (source: Grand View Research). Investment score 47.5/100 (confidence 0.42). Recommended action: License.